ArticleDrug design, development and therapy2026
Obacunone Promotes Functional Recovery After Spinal Cord Injury by Attenuating Neuroinflammation by Targeting the TLR4/MyD88/p38 MAPK Pathway.
Article in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Spinal cord injury (SCI) triggers a complex secondary injury process, among which inflammation and apoptosis are the key factors of nerve injury. Obacunone (Oba) is a natural limonoid that has demonstrated a variety of pharmacological effects, but its role in SCI remains unclear. Methods: Network pharmacology and bioinformatics analysis were employed to predict the functions and mechanisms of Oba in SCI. Subsequently, in vivo validation was conducted in a mouse SCI model, with motor function recovery assessed using open field, footprint, and swimming tests. Spinal cord histomorphology was examined via hematoxylin and eosin (HE) staining and Nissl staining, while the anti‑inflammatory and anti‑apoptotic effects were evaluated by Western blot and immunofluorescence. To further elucidate the underlying mechanisms, a lipopolysaccharide (LPS)-induced inflammatory model in BV‑2 microglial cells was established to study the anti‑inflammatory mechanisms of Oba. Furthermore, a BV‑2/HT22 neuronal co‑culture system was constructed to investigate neuroprotective effects of Oba against apoptosis. Results: In vivo, Oba treatment improved motor function, promoted neural repair, reduced inflammation and apoptosis. Correspondingly, Oba suppressed the expression of LPS-induced pro-inflammatory cytokines in BV-2 cells. In a microglia-neuron co-culture system, Oba protected HT22 neurons from microglia-mediated inflammatory apoptosis. Mechanistically, the anti‑inflammatory effects of Oba were mediated by inhibiting the activation of the TLR4/MyD88/p38 MAPK pathway. Conclusion: This study identifies Oba as an effective compound that mitigates secondary injury by reducing inflammation and apoptosis and promotes nerve repair and functional recovery post-SCI, supporting its potential for further therapeutic development.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.